Kura Oncology Beheer

Beheer criteriumcontroles 3/4

De CEO Kura Oncology is Troy Wilson, benoemd in Mar2015, heeft een ambtstermijn van 9.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.25M, bestaande uit 12.3% salaris en 87.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.75% van de aandelen van het bedrijf, ter waarde € 6.01M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 9.1 jaar.

Belangrijke informatie

Troy Wilson

Algemeen directeur

US$5.3m

Totale compensatie

Percentage CEO-salaris	12.3%
Dienstverband CEO	9.7yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	4yrs
Gemiddelde ambtstermijn bestuur	9.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Troy Wilson's beloning veranderd ten opzichte van Kura Oncology's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$198m
Jun 30 2024	n/a	n/a	-US$182m
Mar 31 2024	n/a	n/a	-US$168m
Dec 31 2023	US$5m	US$646k	-US$153m
Sep 30 2023	n/a	n/a	-US$143m
Jun 30 2023	n/a	n/a	-US$140m
Mar 31 2023	n/a	n/a	-US$137m
Dec 31 2022	US$5m	US$621k	-US$136m
Sep 30 2022	n/a	n/a	-US$135m
Jun 30 2022	n/a	n/a	-US$133m
Mar 31 2022	n/a	n/a	-US$132m
Dec 31 2021	US$9m	US$600k	-US$130m
Sep 30 2021	n/a	n/a	-US$124m
Jun 30 2021	n/a	n/a	-US$114m
Mar 31 2021	n/a	n/a	-US$101m
Dec 31 2020	US$4m	US$573k	-US$90m
Sep 30 2020	n/a	n/a	-US$81m
Jun 30 2020	n/a	n/a	-US$74m
Mar 31 2020	n/a	n/a	-US$68m
Dec 31 2019	US$3m	US$542k	-US$63m
Sep 30 2019	n/a	n/a	-US$61m
Jun 30 2019	n/a	n/a	-US$60m
Mar 31 2019	n/a	n/a	-US$60m
Dec 31 2018	US$5m	US$526k	-US$60m
Sep 30 2018	n/a	n/a	-US$55m
Jun 30 2018	n/a	n/a	-US$49m
Mar 31 2018	n/a	n/a	-US$43m
Dec 31 2017	US$2m	US$472k	-US$35m

Compensatie versus markt: De totale vergoeding ($USD 5.25M ) Troy } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.46M ).

Compensatie versus inkomsten: De vergoeding van Troy is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Troy Wilson (55 yo)

9.7yrs

Tenure

US$5,251,407

Compensatie

Dr. Troy Edward Wilson, Ph D., J.D., is Independent Director of Cartography Biosciences, Inc. from October 2024. He is Co-Founder of Avidity Biosciences Inc. and had been its Executive Chairman since Febru...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Troy Wilson	Chairman	9.7yrs	US$5.25m	0.75% € 6.0m
Kathleen Ford	Chief Operating Officer	5.3yrs	US$2.16m	0.016% € 126.9k
Teresa Bair	Chief Legal Officer & Corporate Secretary	3.1yrs	US$1.98m	0.0069% € 55.8k
Stephen Dale	Chief Medical Officer	4.3yrs	US$2.47m	0.0039% € 31.4k
Thomas Doyle	Senior Vice President of Finance & Accounting	2.8yrs	geen gegevens	0.015% € 123.2k
Pete De Spain	Executive Vice President of Investor Relations & Corporate Communications	7.1yrs	geen gegevens	geen gegevens
Roger Bakale	Senior Vice President of Manufacturing & Supply Chain	4.8yrs	geen gegevens	geen gegevens
Maureen Clancy	VP and Global Head of Program Leadership & Project Management	3.7yrs	geen gegevens	geen gegevens
Mollie Leoni	Executive Vice President of Clinical Development	2.8yrs	geen gegevens	geen gegevens
Brian Powl	Chief Commercial Officer	1.3yrs	geen gegevens	geen gegevens
Francis Burrows	Senior Vice President of Translational Research	no data	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van KUR wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Troy Wilson	Chairman	9.7yrs	US$5.25m	0.75% € 6.0m
Daniel Von Hoff	Clinical Advisor	no data	geen gegevens	geen gegevens
Thomas Malley	Independent Director	9.1yrs	US$275.69k	0% € 0
Mary Szela	Independent Director	6yrs	US$279.80k	0% € 0
Faheem Hasnain	Lead Independent Director	9.6yrs	US$300.54k	0.031% € 248.7k
Frank McCormick	Scientific Advisor	no data	geen gegevens	geen gegevens
Neal Rosen	Scientific Advisor	no data	geen gegevens	geen gegevens
Kevan Shokat	Chairman of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Alan Houghton	Clinical Advisor	no data	geen gegevens	geen gegevens
Josep Tabernero	Clinical Advisor	no data	geen gegevens	geen gegevens
Steven Horwitz	Clinical Advisor	no data	geen gegevens	geen gegevens
Carol Schafer	Independent Director	3.4yrs	US$279.05k	0% € 0

9.1yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KUR wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.1 jaar).

Kura Oncology Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors

Insufficient new directors

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Chief Medical Officer recently sold €56k worth of stock

Kura Oncology, Inc. Announces Executive Changes

Recent updates

Kura Oncology, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors

Kura Oncology Announces Fda Clearance of Ind Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (Gist)

Kura Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Now 20% undervalued

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 2500 Value Index

Insufficient new directors

New minor risk - Share price stability

Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

Kura Oncology, Inc. to Report Q1, 2024 Results on May 02, 2024

Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Now 21% undervalued

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

New major risk - Share price stability

Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC

Kura Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Kura Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASG12C Inhibitors in Non-Small Cell Lung Cancer

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Kura Oncology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kura Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $99.999707 million.

Kura Oncology, Inc. Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib At 2023 European Hematology Association Congress

Kura Oncology, Inc. to Report Q1, 2023 Results on May 10, 2023

Kura Oncology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Kura Oncology, Inc. Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

Chief Medical Officer recently sold €56k worth of stock

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, A Next-Generation Farnesyl Transferase Inhibitor

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib

Kura Oncology, Inc. announced that it expects to receive $150.000003 million in funding from Bristol-Myers Squibb Company,

Kura Oncology, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Kura Oncology, Inc. Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

Kura Oncology, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Independent Director Robert Hoffman has left the company

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 3000E Index

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

New 90-day low: €22.00

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day low: €24.40

Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 At American Society of Hematology Annual Meeting

New 90-day high: €29.40

Kura Oncology, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Kura Oncology, Inc. Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Ka Inhibitor in Head and Neck Squamous Cell Carcinoma

New 90-day high: €26.40

Kura Oncology, Inc. to Report Q1, 2020 Results on May 04, 2020

New 90-day high: €24.80

New 90-day high - €18.50

New 90-day high - €17.50

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd